Literature DB >> 29159742

Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Dario Baratti1, Shigeki Kusamura2, Massimo Milione3, Federica Bruno2, Marcello Guaglio2, Marcello Deraco2.   

Abstract

BACKGROUND: Controversies still persist regarding the terminology and pathologic classification of appendiceal mucinous neoplasms and associated pseudomyxoma peritonei (PMP). We assessed reproducibility and prognostic significance of the classification recently proposed by the Peritoneal Surface Oncology Group International (PSOGI).
METHODS: A prospective database of 265 PMP patients uniformly treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) from 1995 to 2017 was reviewed. According to the PSOGI, peritoneal disease was retrospectively classified into three categories: low-grade (LG-PMP), high-grade (HG-PMP), and signet-ring cells (SRC-PMP). Acellular mucin (AC) was classified separately. The extent of peritoneal involvement was quantified by the peritoneal cancer index (PCI).
RESULTS: Twenty-six patients were diagnosed with AC (9.8%), 197 with LG-PMP (74.4%), 38 with HG-PMP (14.3%), and 4 with SRC-PMP (1.5%). In the overall series, median follow-up was 65.5 months (95% confidence interval 53.7-78.8) and 10-year overall survival was 62.9% (median 148.7 months). Operative death occurred in 10 patients (3.8%) and major complications occurred in 89 patients (33.6%). Ten-year survival was 89.6% for AC, 63.2% for LG-PMP, 40.1% for HG-PMP, and 0 for SRC-PMP. In a multivariate model, the World Health Organization (WHO) pathological classification independently correlated with survival (p = 0.028). In a separate model, the PSOGI classification did not reach statistical significance (p = 0.149). Completeness of cytoreduction and PCI > 22 correlated with prognosis in both models.
CONCLUSIONS: AC and SRC-PMP pathological categories of the PSOGI classification identified two subsets of patients with favorable and exceedingly dismal prognosis, respectively. It remains unclear whether the PSOGI classification might provide better prognostic stratification than the current WHO classification. Further studies in larger prospective series are needed.

Entities:  

Mesh:

Year:  2017        PMID: 29159742     DOI: 10.1245/s10434-017-6252-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

1.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for resectable peritoneal metastases is feasible in elderly patients.

Authors:  Walid Ezzedine; Diane Mege; Mathilde Aubert; Julie Duclos; Rémy Le Huu Nho; Igor Sielezneff; Nicolas Pirro
Journal:  Updates Surg       Date:  2021-02-06

Review 2.  The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan.

Authors:  Toshiyuki Kitai
Journal:  Surg Today       Date:  2020-11-13       Impact factor: 2.549

Review 3.  New insights in the pathology of peritoneal surface malignancy.

Authors:  Norman John Carr
Journal:  J Gastrointest Oncol       Date:  2021-04

4.  Validating the PSOGI classification of peritoneal disease from non-carcinoid epithelial appendiceal neoplasms in the curative and palliative setting: an observational retrospective study.

Authors:  Nina Farrokhnia; Henrik Benoni; Lana Ghanipour; Peter H Cashin
Journal:  J Gastrointest Oncol       Date:  2022-04

5.  Enhanced computed tomography imaging features predict tumor grade in pseudomyxoma peritonei.

Authors:  Pengtao Sun; Xinbao Li; Lingling Wang; Rengui Wang; Xuechao Du
Journal:  Quant Imaging Med Surg       Date:  2022-04

6.  Validation of a Nomogram to Predict Recurrence in Patients with Mucinous Neoplasms of the Appendix with Peritoneal Dissemination After Cytoreductive Surgery and HIPEC.

Authors:  L Martín Román; P Lozano; D Baratti; S Kusamura; M Deraco; W Vásquez; L González Bayón
Journal:  Ann Surg Oncol       Date:  2022-07-25       Impact factor: 4.339

Review 7.  Essentials for Pathological Evaluation of Peritoneal Surface Malignancies and Synoptic Reporting of Cytoreductive Surgery Specimens-A review and evidence-based guide.

Authors:  Aditi Bhatt; Suniti Mishra; Loma Parikh; Sandeep Sheth; Imran Gorur
Journal:  Indian J Surg Oncol       Date:  2019-03-19

8.  Updated staging and patient outcomes in low-grade appendiceal mucinous neoplasms.

Authors:  Samuel J Ballentine; Jacquelyn Carr; Eliahu Y Bekhor; Umut Sarpel; Alexandros D Polydorides
Journal:  Mod Pathol       Date:  2020-07-29       Impact factor: 7.842

9.  The role of mucin cell-free DNA detection as a new marker for the study of acellular pseudomyxoma peritonei of appendicular origin by liquid biopsy.

Authors:  Damián García-Olmo; Susana Olmedillas-López; Delia Cortés-Guiral; Pedro Villarejo; Irene López Rojo; Héctor Guadalajara; Soledad García Gómez-Heras; Mariano García-Arranz
Journal:  Ther Adv Med Oncol       Date:  2020-06-24       Impact factor: 8.168

10.  Development and validation of prognostic nomograms for pseudomyxoma peritonei patients after surgery: A population-based study.

Authors:  Peng Chen; Lan Su; Wenming Yang; Jianhao Zhang; Yong Wang; Cun Wang; Yongyang Yu; Lie Yang; Zongguang Zhou
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.